@JohnKastelein @Drlipid @nationallipid @society_eas @TheFHFoundation So was this one when common sense prevailed when interpreting RCT for making guidelines: https://t.co/LXivVklyv3
@DanClintonRN @ExpertLipid This is probably the data they are referencing. Not saying it’s justified or correct. Just pointing it out. 🤷🏼♂️ https://t.co/CvHVt8PE06 https://t.co/KgJkF2FsQ8
@SteveDa39872898 https://t.co/UcwQ0IZ2AO and another study showong the same thing and no funding.. https://t.co/ZfIWfXRTfc
スタチンは本当にLDLを下げれば下げるほど、心血管イベントを減らすのでしょうか? J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. PMID:25082583 https://t.co/i477WCdBTA https://t.co/invbkzXlLk
To demonstrate how this applies to research and how asinine the assertion that ARRs are "small" or "irrelevant" is, this is what is seen when a meta-analysis investigates large differences in achieved LDL concentrations in RCTs with decent follow-ups. http
@DrScottMurray @ethanjweiss Benefits of statins are directly proportional to LDL/apoB reductions, not coagulation factors https://t.co/XOURafRWna
@BennyFrank3rd @BenBikmanPhD Depends on what study you cite: https://t.co/Ceqnb0J01p
@TuckerGoodrich @puddleg Those guys ignore everything that's contained in this paper: https://t.co/H5noRssQXc
@TuckerGoodrich @wabmester @mvholmes While you look, here's a couple newer ones that are related. No sign of pleiotropic effects: https://t.co/H5noRssQXc https://t.co/0yRBZLrCdy
RT @drpablocorral: High quality EVIDENCE. Very Low Levels of LDLc and the Risk for CV Events: A Meta-Analysis of Statin Trials https://t.co…
RT @drpablocorral: High quality EVIDENCE. Very Low Levels of LDLc and the Risk for CV Events: A Meta-Analysis of Statin Trials https://t.co…
RT @drpablocorral: High quality EVIDENCE. Very Low Levels of LDLc and the Risk for CV Events: A Meta-Analysis of Statin Trials https://t.co…
RT @drpablocorral: High quality EVIDENCE. Very Low Levels of LDLc and the Risk for CV Events: A Meta-Analysis of Statin Trials https://t.co…
RT @drpablocorral: High quality EVIDENCE. Very Low Levels of LDLc and the Risk for CV Events: A Meta-Analysis of Statin Trials https://t.co…
High quality EVIDENCE. Very Low Levels of LDLc and the Risk for CV Events: A Meta-Analysis of Statin Trials https://t.co/5ZHJWepkNl
RT @ArsenaultBenoit: We found the opposite in a meta-analysis of statin trials https://t.co/7vLCJdgNXH @skathire @MichaelJBlaha https://t.c…
RT @ArsenaultBenoit: We found the opposite in a meta-analysis of statin trials https://t.co/7vLCJdgNXH @skathire @MichaelJBlaha https://t.c…
We found the opposite in a meta-analysis of statin trials https://t.co/7vLCJdgNXH @skathire @MichaelJBlaha https://t.co/pCIfkwpoGd
RT @ArsenaultBenoit: @dr_kevinlee @fitly75 @PauliOhukainen IVUS & outcomes studies: those who achieve lowest LDL R those with lowest risk h…
@dr_kevinlee @fitly75 @PauliOhukainen IVUS & outcomes studies: those who achieve lowest LDL R those with lowest risk https://t.co/Fo1PFlcvW4
@karlaag03 @Drlipid @lipiddoc This is not based on our patient-based analysis of statin trials http://t.co/NfqBk59hiX http://t.co/pjkRzyFFrM
@karlaag03 @Drlipid @lipiddoc This is not based on our patient-based analysis of statin trials http://t.co/NfqBk59hiX http://t.co/pjkRzyFFrM
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events http://t.co/laQu0DwCNG
Metanalisis demoledor. cuanto mas bako mejor. Meta-Analysis of Statin Trials http://t.co/WuogrpBC4e
Metanalisis demoledor. cuanto mas bako mejor. Meta-Analysis of Statin Trials http://t.co/WuogrpBC4e
Metanalisis demoledor. cuanto mas bako mejor. Meta-Analysis of Statin Trials http://t.co/WuogrpBC4e
Metanalisis demoledor. cuanto mas bako mejor. Meta-Analysis of Statin Trials http://t.co/WuogrpBC4e
Metanalisis demoledor. cuanto mas bako mejor. Meta-Analysis of Statin Trials http://t.co/WuogrpBC4e
Metanalisis demoledor. cuanto mas bako mejor. Meta-Analysis of Statin Trials http://t.co/WuogrpBC4e
Metanalisis demoledor. cuanto mas bako mejor. Meta-Analysis of Statin Trials http://t.co/WuogrpBC4e
Very low levels of atherogenic lipoproteins and the risk for cardio... - PubMed - NCBI - http://t.co/a9x5Aw68s1
@vesiadog Patients who achieve very low LDL-C levels have a lower risk for MACE than those who do not http://t.co/wJ3YD3a6Mx
'Lower is better' for LDL, a new meta-analysis. 'How low should we go' - a key question in dyslipidaemia management http://t.co/4Qoth7mN70
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. http://t.co/7LPWnt6HGt
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin... http://t.co/XPI7Inonrx
Abstract on new statin meta-analysis re low LDLc and apoB. http://t.co/e1R9hTCN8W If you can also try and get editorial #nationallipid
@MacSmiley @Drlipid http://t.co/USy7R6er3Y http://t.co/29iYCneaWv Individuals with LDL-cholesterol levels <50 mg/dL = lower risk
【スタチン服用例の到達LDL-C値別心血管系イベントハザード比 [vs LDL>175]は,75 - 100mg/dLで 0.56,50 - 75で0.51,<50で0.44:無作為化試験8報メタ解析】 JACC http://t.co/F2GGaZsnYK
【スタチン服用例の到達LDL-C値別心血管系イベントハザード比 [vs LDL>175]は,75 - 100mg/dLで 0.56,50 - 75で0.51,<50で0.44:無作為化試験8報メタ解析】 JACC http://t.co/F2GGaZsnYK
Abstract on new statin meta-analysis re low LDLc and apoB. http://t.co/e1R9hTCN8W If you can also try and get editorial #nationallipid
Abstract on new statin meta-analysis re low LDLc and apoB. http://t.co/e1R9hTCN8W If you can also try and get editorial #nationallipid
>40% of pts Rx with high dose statin do not reach LDL goal and lower LDL is associated with lower CV mortality http://t.co/CmU7PAPXy3
Our paper on very low #cholesterol levels and #heartdisease risk just out in JACC @ACCinTouch http://t.co/DuUPkRIxyL
Our paper on very low #cholesterol levels and #heartdisease risk just out in JACC @ACCinTouch http://t.co/DuUPkRIxyL